SCHEDULE: Major Stakeholders Increase Cocrystal Pharma Stake

Key investors, including OPKO Health and entities controlled by Dr. Phillip Frost, have collectively increased their beneficial ownership in Cocrystal Pharma, Inc., signaling strong conviction in the company's prospects.

Summary

• OPKO Health, Inc. acquired 5,474,053 shares of Cocrystal Pharma, Inc. common stock for $5,000,000 on July 31, 2026, increasing its beneficial ownership to 29.6%.
• Frost Gamma Investments Trust (FGIT) acquired 85,000 shares for approximately $80,404.18 between August 3-5, 2026, increasing its beneficial ownership to 13.6%.
• Dr. Phillip Frost, M.D. and Steven D. Rubin, both directors of Cocrystal Pharma, also hold shares and options, with their combined beneficial ownership (including FGIT) reaching 13.9% for Dr. Frost and 14.1% for Mr. Rubin.
• The Reporting Persons have entered into a Stockholders Rights Agreement, including voting agreements and a right of first refusal on future equity financings up to $70 million.
• The filing indicates that these acquisitions are for investment purposes, with potential for future actions based on various factors.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, indicating significant investment and strategic alignment among key stakeholders, though it lacks specific forward-looking financial guidance.

Positives

• Significant investment by OPKO Health, Inc. ($5,000,000) and Frost Gamma Investments Trust (approx. $80,404) demonstrates confidence in Cocrystal Pharma.
• Combined beneficial ownership of key stakeholders (OPKO, Dr. Frost, FGIT, Mr. Rubin) represents a substantial portion of the company's outstanding shares (collectively over 57%).
• The Stockholders Rights Agreement provides a framework for continued collaboration and alignment among major shareholders.
• Right of first refusal on future equity financings offers protection and potential participation for these investors.

Negatives

• The filing does not provide specific financial performance metrics or forward-looking guidance from Cocrystal Pharma itself.
• The significant ownership concentration by a few entities could potentially limit the free float of shares.

Risks

• Future actions regarding investments in Cocrystal Pharma are subject to various factors including the Issuer's financial position, strategic direction, board actions, stock price, and general market conditions.
• The Stockholders Rights Agreement, while providing alignment, also imposes certain voting restrictions and rights of first refusal that could impact future transactions.

Future Outlook

The Reporting Persons intend to review their investments in Cocrystal Pharma on a continuing basis and may take actions such as purchasing additional shares, selling holdings, or engaging in hedging transactions, depending on various factors including the Issuer's financial position and strategic direction.

Management Comments

• OPKO acquired the shares of Common Stock for investment purposes.
• Dr. Frost and FGIT acquire shares of common stock for investment purposes.
• In their capacity as directors of the Issuer, Dr. Frost and Mr. Rubin may, from time to time, formulate plans or proposals regarding the Issuer or its securities for consideration by the board of directors of the Issuer and the Issuer's management.
• OPKO intends to review its investments in the Issuer on a continuing basis.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by established healthcare entities like OPKO Health in smaller biopharmaceutical companies are common, often indicating a belief in the target's technology or market potential, especially in the competitive drug development landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased concentration of ownership by key entities may influence market dynamics and future strategic decisions.
• Management/Board: Dr. Frost and Mr. Rubin, as directors, are involved in decisions and may formulate proposals.
• Creditors/Suppliers: Indirect impact through potential future strategic shifts or capital raises by Cocrystal Pharma.

Next Steps

• OPKO Health, Inc. will continue to review its investments in Cocrystal Pharma.
• Reporting Persons may take future actions regarding their investments based on various factors.

Key Dates

Recommendation

The filing indicates significant investment and strategic alignment among major stakeholders, suggesting a positive outlook. However, the lack of specific operational or financial updates from Cocrystal Pharma itself, and the fact that this is primarily an ownership disclosure, warrants a 'hold' recommendation pending further company-specific news.

Keywords

Cocrystal Pharma, OPKO Health, Phillip Frost, Steven Rubin, Schedule 13D, Beneficial Ownership, Securities Purchase Agreement, Stockholders Rights Agreement